How many insider trades does FilingIQ track for SYRS?

FilingIQ tracks 307 Form 4 insider transactions for SYRS (Syros Pharmaceuticals, Inc.), covering filings from Jul 6, 2016 onwards. 0 of those were filed in the last 90 days.

Are SYRS insiders net buyers or net sellers?

Across the full Form 4 history for SYRS, 32 transactions (10%) were open-market purchases and 58 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does SYRS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is SYRS in?

Syros Pharmaceuticals, Inc. (SYRS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5366.

SYRS insider trading

OTC Markets OTCPK Healthcare

Syros Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

307

Last 90 days

Buys / sells

10% / 19%

Market cap

$5366

About Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Company website: www.syros.com

SYRS insider activity at a glance

FilingIQ has scored 307 insider transactions for SYRS since Jul 6, 2016. The most recent filing in our index is dated Dec 2, 2024.

Across the full history, 32 open-market purchases and 58 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on SYRS insider trades is 51.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live SYRS trades on FilingIQ Raw filings on SEC EDGAR

Latest SYRS Form 4 filings

Chee Conley President & CEO

S Nov 18, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding SYRS

Samsara BioCapital, LLC

$2.35M · 0.5% of AUM

Frequently asked

How many insider trades does FilingIQ track for SYRS?: FilingIQ tracks 307 Form 4 insider transactions for SYRS (Syros Pharmaceuticals, Inc.), covering filings from Jul 6, 2016 onwards. 0 of those were filed in the last 90 days.
Are SYRS insiders net buyers or net sellers?: Across the full Form 4 history for SYRS, 32 transactions (10%) were open-market purchases and 58 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SYRS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is SYRS in?: Syros Pharmaceuticals, Inc. (SYRS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5366.

Methodology & sources

Every SYRS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.